Anthracycline cardiotoxicity — prevention
- Limit cumulative anthracycline exposure when possible
- Baseline and serial LV function in at-risk patients
- Dexrazoxane reduces cardiotoxicity in selected patients
- Liposomal doxorubicin can lower cardiac exposure
- Control HTN and other CV risk
- New dysfunction → guideline-directed HF therapy
Use at a glance
- Limit cumulative anthracycline exposure when possible
Choosing treatment
- Liposomal doxorubicin can lower cardiac exposure
- New dysfunction → guideline-directed HF therapy
Practical pearls
- Baseline and serial LV function in at-risk patients
Treatment selection
- Dexrazoxane reduces cardiotoxicity in selected patients
- Control HTN and other CV risk
Self-check
- What is recommended for New dysfunction in Anthracycline cardiotoxicity — prevention?
guideline-directed HF therapy.
Drugs used for this (1)
All clinical uses · Open the interactive console ↗
